<DOC>
	<DOCNO>NCT03012360</DOCNO>
	<brief_summary>Antimicrobial treatment could beneficial patient ventilator-associated tracheobronchitis ( VAT ) . The hypothesis study antibiotic treatment VAT ( 3 7 day ) , compare antibiotic treatment , would reduce incidence transition VAT ventilator-associated pneumonia ( VAP ) .</brief_summary>
	<brief_title>Antimicrobial Treatment Patients With Ventilator-associated Tracheobronchitis</brief_title>
	<detailed_description>The main objective randomize controlled multicenter double-blind trial ass efficiency two duration ( 3 7 day ) antibiotic treatment VAT , compare antibiotic treatment , reduce incidence transition VAT ventilator-associated pneumonia ( VAP ) . Secondary objective determine impact two duration ( 3 7 day ) antibiotic treatment VAT , compare antibiotic treatment , : - duration mechanical-ventilation free day - duration antibiotic free day - length ICU stay - mortality day 28 day 90 - incidence ICU-acquired colonization relate multidrug resistant ( MDR ) bacteria - incidence ICU-acquired infection relate MDR bacteria - incidence ventilator-associated event After informed consent , patient randomize ( 1:1:1 ) receive 0 ( control group ) , 3 7 day ( experimental group ) antibiotic treatment VAT Antibiotic treatment standardize , base time onset VAT , presence risk factor MDR bacteria : - patient early-onset VAT risk factor MDR bacteria receive ceftriaxone ( 2 g iv every 24h ) . - patient late-onset VAT ( day 4 mechanical ventilation ) , least one risk factor MDR bacteria receive imipenem ( 1 g iv every 8h ) , ciprofloxacin ( 400 mg iv every 8h ) empirical treatment . When methicillin-resistant Staphylococcus aureus suspect , linezolid ( 600 mg iv every 12h ) add empirical treatment . Patients randomize control group receive 7 day placebo , randomize first experimental arm ( 3 day antibiotic ) receive 4 day placebo .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>All adult patient hospitalize ICU first episode VAT diagnose &gt; 48 hour start invasive mechanical ventilation eligible study . VAT define use follow criterion : 1. absence new infiltrate chest X ray 2. two three follow condition : fever &gt; 38.5 °C &lt; 36.5 , leucocyte count &gt; 12 000 cell per μL &lt; 4000 cell per μL purulent tracheal secretion 3. positive tracheal aspirate ( ≥105 cfu/mL ) longterm tracheostomy ICU admission modify Clinical Pulmonary Infection Score ( CPIS ) ≥6 day randomization patient develop VAP VAT patient already receive antibiotic active microorganism responsible VAT severe immunosuppression pregnancy breastfeed patient &lt; 18 year patient already include another study , potential interaction primary objective current study know resistance imipenem ciprofloxacin bacteria responsible VAT treatment limitation decision moribund patient ( likely die within 24 h ) allergy study drug : hypersensitivity carbapenem , severe hypersensitivity ( example anaphylactic reaction severe cutaneous reaction ) antibiotic form betalactam group ( penicillin cephalosporin ) , severe hypersensitivity ( example anaphylactic reaction ) antibiotic betalactam group ( penicillin , monobactam carbapenem ) , hypersensitivity quinolones</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Infectiology</keyword>
	<keyword>Biology infectious agent</keyword>
	<keyword>Hygiene</keyword>
	<keyword>Pneumology</keyword>
	<keyword>Critical Care</keyword>
</DOC>